The Boulder Peptide Society and Ipsen are pleased to bring you the inaugural Peptide Showcase East in Cambridge, MA, March 14-15, 2016. .
The Peptide Showcase will bring together thought leaders in biotech, pharma, and academic institutions to present the most current of paradigms in peptide therapeutics, and to uncover solutions to challenges in peptide drug discovery and development. Peptide Showcase East will be an opportunity for companies to "showcase" new ideas, technologies, and pipeline assets in short business oriented presentations. An electronic partnering forum will be used for pre-arranged one-on-one business meetings between technology providers, licensing partners, and investors. Modeled after the highly successful Peptide Showcase held annually at the Boulder Peptide Symposium, this event, with support from Ipsen, a founding sponsor and world leader in peptide therapeutics, will focus exclusively on innovations in the peptide therapeutics technology space. The event will be held at the Microsoft New England Research and Development Center, located in Kendall Square; Cambridge’s’ iconic innovation district,.
Apply to Present or Register early for best pricing!
Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors.
Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Cambridge, US; Les Ulis, France; Oxford, UK). Moreover, Ipsen has an active policy of partnerships.
Peptides: long-standing expertise
Ipsen has a long standing expertise, ranging from discovery to delivery of peptides that is being leveraged to create highly differentiated drugs for targets that are not readily addressed by small molecules or antibodies. Ipsen Bioscience, Ipsen’s new R&D center in Cambridge, which opened in 2014 and was inaugurated on April 1, 2015, develops highly differentiated peptide-based drugs to fulfill unmet medical needs in endocrinology and oncology.